Artivion price target raised to $42 from $33 at Citizens JMP

Citizens JMP raised the firm’s price target on Artivion (AORT) to $42 from $33 and keeps an Outperform rating on the shares. The Q2 results reflected a beat and raise, as well as positive incremental product and clinical updates, the analyst tells investors in a research note. The firm continues to be impressed by Artivion’s strong fundamentals, dependable base business, complementary advanced stent graft division, and notable EBITDA growth and margin profile, as well as its potential for upside from notable shots on goal slated for the years ahead.